Stock ACRV ACRIVON THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Acrivon Therapeutics, Inc.

Equities

ACRV

US0048901096

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
7.72 USD +1.98% Intraday chart for Acrivon Therapeutics, Inc. -2.89% +56.91%
May. 14 Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 30 North American Morning Briefing : More Earnings -2- DJ

Evolution of the average Target Price on Acrivon Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

21712566e46702f203f57d.lZj5Pj7ySGjcK9s7gMhyBwTZ1TVO5aVudBTlsmcx3KY.09aRTXKwHAe4RK9Uyr8bMmOb7EMHq_Y3M3LR8w9FmN7HrrIISrN-HZRomg~8e89da60b5148a59f446f850ed612ea1

Analyst Recommendations on Acrivon Therapeutics, Inc.

Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral MT
Piper Sandler Adjusts Price Target on Acrivon Therapeutics to $30 From $26, Keeps Overweight Rating MT
Ladenburg Thalmann Cuts Price Target on Acrivon Therapeutics to $14 From $18, Maintains Buy Rating MT
JMP Securities Starts Acrivon Therapeutics With Market Outperform Rating, $14 Price Target MT
Maxim Initiates Acrivon Therapeutics at Buy Rating With $24 Price Target MT
Oppenheimer Initiates Coverage on Acrivon Therapeutics With Outperform Rating, $25 Price Target MT
BMO Capital Initiates Acrivon Therapeutics at Outperform With $25 Price Target MT
HC Wainwright Initiates Coverage on Acrivon Therapeutics With Buy Rating, $24 Price Target MT
Jefferies Starts Acrivon Therapeutics at Buy With $17 Price Target MT
Piper Sandler Starts Acrivon Therapeutics at Overweight With $25 Price Target MT
Cowen Starts Acrivon Therapeutics at Outperform MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
7.72 USD
Average target price
22.12 USD
Spread / Average Target
+186.59%
High Price Target
30 USD
Spread / Highest target
+288.60%
Low Price Target
17 USD
Spread / Lowest Target
+120.21%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Acrivon Therapeutics, Inc.

Ladenburg Thalmann
Piper Sandler
JMP Securities
Maxim
Oppenheimer
BMO Capital
HC Wainwright
Jefferies & Co.
Cowen

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ACRV Stock
  4. Consensus Acrivon Therapeutics, Inc.